Circulating miRNA as fine regulators of the physiological responses to physical activity: Pre-analytical warnings for a novel class of biomarkers

Clinical Biochemistry

Volumn 49, Issue 18, 2016, Pages 1331-1339

  Lombardi, Giovanni ^a   Perego, Silvia ^a   Sansoni, Veronica ^a   Banfi, Giuseppe ^a,b  

^a IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Athletes; miRNA; Physical activity; Pre analytical phase

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; MICRORNA;

ALTITUDE; ANALYTIC METHOD; ATHLETE; DIET SUPPLEMENTATION; DOPING; ENVIRONMENTAL EXPOSURE; EXERCISE; FALSE POSITIVE RESULT; GENE EXPRESSION REGULATION; HUMAN; NONHUMAN; PHYSICAL ACTIVITY; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; REVIEW; RNA DEGRADATION; SPORTS MEDICINE; BLOOD; DIET; DIETARY SUPPLEMENT;

BIOMARKERS; DIET; DIETARY SUPPLEMENTS; DOPING IN SPORTS; EXERCISE; HUMANS; MICRORNAS; SPORTS MEDICINE;

EID: 84999592881     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2016.09.017     Document Type: Review

References (141)

1. [1] Lee, R.C., Feinbaum, R.L., Ambros, V., The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75 (1993), 843–854.
2. [2] Lagos-Quintana, M., Rauhut, R., Lendeckel, W., Tuschl, T., Identification of novel genes coding for small expressed RNAs. Science 294 (2001), 853–858.
3. [3] Reinhart, B.J., Weinstein, E.G., Rhoades, M.W., Bartel, B., Bartel, D.P., MicroRNAs in plants. Genes Dev. 16 (2002), 1616–1626.
4. [4] Grundhoff, A., Sullivan, C.S., Virus-encoded microRNAs. Virology 411 (2011), 325–343.
5. [5] Griffiths-Jones, S., Grocock, R.J., van Dongen, S., Bateman, A., Enright, A.J., miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 34 (2006), D140–D144.
6. [6] Kim, V.N., Nam, J.W., Genomics of microRNA. Trends Genet. 22 (2006), 165–173.
7. [7] Ghorai, A., Ghosh, U., miRNA gene counts in chromosomes vary widely in a species and biogenesis of miRNA largely depends on transcription or post-transcriptional processing of coding genes. Front. Genet., 5, 2014, 100.
8. [8] Lujambio, A., Calin, G.A., Villanueva, A., Ropero, S., Sanchez-Cespedes, M., Blanco, D., et al. A microRNA DNA methylation signature for human cancer metastasis. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 13556–13561.
9. [9] Hammond, S.M., An overview of microRNAs. Adv. Drug Deliv. Rev. 87 (2015), 3–14.
10. [10] Bernstein, E., Kim, S.Y., Carmell, M.A., Murchison, E.P., Alcorn, H., Li, M.Z., et al. Dicer is essential for mouse development. Nat. Genet. 35 (2003), 215–217.
11. [11] Suh, M.R., Lee, Y., Kim, J.Y., Kim, S.K., Moon, S.H., Lee, J.Y., et al. Human embryonic stem cells express a unique set of microRNAs. Dev. Biol. 270 (2004), 488–498.
12. [12] Murchison, E.P., Partridge, J.F., Tam, O.H., Cheloufi, S., Hannon, G.J., Characterization of Dicer-deficient murine embryonic stem cells. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 12135–12140.
13. [13] Morrow, D.A., de Lemos, J.A., Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 115 (2007), 949–952.
14. [14] Hackl, M., Heilmeier, U., Weilner, S., Grillari, J., Circulating microRNAs as novel biomarkers for bone diseases — complex signatures for multifactorial diseases?. Mol. Cell. Endocrinol. 432 (2016), 83–95.
15. [15] Mestdagh, P., Hartmann, N., Baeriswyl, L., Andreasen, D., Bernard, N., Chen, C., et al. Evaluation of quantitative miRNA expression platforms in the microRNA quality control (miRQC) study. Nat. Methods 11 (2014), 809–815.
16. [16] Nelson, P.T., Wang, W.X., Wilfred, B.R., Tang, G., Technical variables in high-throughput miRNA expression profiling: much work remains to be done. Biochim. Biophys. Acta 2008 (1779), 758–765.
17. [17] Chen, X., Ba, Y., Ma, L., Cai, X., Yin, Y., Wang, K., et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18 (2008), 997–1006.
18. [18] Baggish, A.L., Hale, A., Weiner, R.B., Lewis, G.D., Systrom, D., Wang, F., et al. Dynamic regulation of circulating microRNA during acute exhaustive exercise and sustained aerobic exercise training. J. Physiol. 589 (2011), 3983–3994.
19. [19] Takahashi, K., Yokota, S., Tatsumi, N., Fukami, T., Yokoi, T., Nakajima, M., Cigarette smoking substantially alters plasma microRNA profiles in healthy subjects. Toxicol. Appl. Pharmacol. 272 (2013), 154–160.
20. [20] Witwer, K.W., XenomiRs and miRNA homeostasis in health and disease: evidence that diet and dietary miRNAs directly and indirectly influence circulating miRNA profiles. RNA Biol. 9 (2012), 1147–1154.
21. [21] Shende, V.R., Goldrick, M.M., Ramani, S., Earnest, D.J., Expression and rhythmic modulation of circulating microRNAs targeting the clock gene Bmal1 in mice. PLoS One, 6, 2011, e22586.
22. [22] Neal, C.S., Michael, M.Z., Pimlott, L.K., Yong, T.Y., Li, J.Y., Gleadle, J.M., Circulating microRNA expression is reduced in chronic kidney disease. Nephrol. Dial. Transplant. 26 (2011), 3794–3802.
23. [23] Ludwig, N., Leidinger, P., Becker, K., Backes, C., Fehlmann, T., Pallasch, C., et al. Distribution of miRNA expression across human tissues. Nucleic Acids Res. 44 (2016), 3865–3877.
24. [24] Weber, J.A., Baxter, D.H., Zhang, S., Huang, D.Y., Huang, K.H., Lee, M.J., et al. The microRNA spectrum in 12 body fluids. Clin. Chem. 56 (2010), 1733–1741.
25. [25] Wang, J., Chen, J., Sen, S., MicroRNA as biomarkers and diagnostics. J. Cell. Physiol. 231 (2016), 25–30.
26. [26] Ardekani, A.M., Naeini, M.M., The role of microRNAs in human diseases. Avicenna J. Med. Biotechnol. 2 (2010), 161–179.
27. [27] Lu, J., Getz, G., Miska, E.A., Alvarez-Saavedra, E., Lamb, J., Peck, D., et al. MicroRNA expression profiles classify human cancers. Nature 435 (2005), 834–838.
28. [28] Butz, H., Patocs, A., Technical aspects related to the analysis of circulating microRNAs. EXS 106 (2015), 55–71.
29. [29] Lombardi, G., Sanchis-Gomar, F., Perego, S., Sansoni, V., Banfi, G., Implications of exercise-induced adipo-myokines in bone metabolism. Endocrine, 2015.
30. [30] Russell, A.P., Hesselink, M.K., Lo, S.K., Schrauwen, P., Regulation of metabolic transcriptional co-activators and transcription factors with acute exercise. FASEB J. 19 (2005), 986–988.
31. [31] Banfi, G., Colombini, A., Lombardi, G., Lubkowska, A., Metabolic markers in sports medicine. Adv. Clin. Chem. 56 (2012), 1–54.
32. [32] Guller, I., Russell, A.P., MicroRNAs in skeletal muscle: their role and regulation in development, disease and function. J. Physiol. 588 (2010), 4075–4087.
33. [33] Ai, J., Zhang, R., Li, Y., Pu, J., Lu, Y., Jiao, J., et al. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem. Biophys. Res. Commun. 391 (2010), 73–77.
34. [34] McCarthy, J.J., Esser, K.A., MicroRNA-1 and microRNA-133a expression are decreased during skeletal muscle hypertrophy. J. Appl. Physiol. 102 (2007), 306–313.
35. [35] Xu, T., Liu, Q., Yao, J., Dai, Y., Wang, H., Xiao, J., Circulating microRNAs in response to exercise. Scand. J. Med. Sci. Sports 25 (2015), e149–e154.
36. [36] Russell, A.P., Lamon, S., Exercise, skeletal muscle and circulating microRNAs. Prog. Mol. Biol. Transl. Sci. 135 (2015), 471–496.
37. [37] Aoi, W., Ichikawa, H., Mune, K., Tanimura, Y., Mizushima, K., Naito, Y., et al. Muscle-enriched microRNA miR-486 decreases in circulation in response to exercise in young men. Front. Physiol., 4, 2013, 80.
38. [38] Nielsen, S., Akerstrom, T., Rinnov, A., Yfanti, C., Scheele, C., Pedersen, B.K., et al. The miRNA plasma signature in response to acute aerobic exercise and endurance training. PLoS One, 9, 2014, e87308.
39. [39] Mooren, F.C., Viereck, J., Kruger, K., Thum, T., Circulating microRNAs as potential biomarkers of aerobic exercise capacity. Am. J. Physiol. Heart Circ. Physiol. 306 (2014), H557–H563.
40. [40] Baggish, A.L., Park, J., Min, P.K., Isaacs, S., Parker, B.A., Thompson, P.D., et al. Rapid upregulation and clearance of distinct circulating microRNAs after prolonged aerobic exercise. J. Appl. Physiol. 116 (2014), 522–531.
41. [41] Radom-Aizik, S., Zaldivar, F. Jr., Leu, S.Y., Adams, G.R., Oliver, S., Cooper, D.M., Effects of exercise on microRNA expression in young males peripheral blood mononuclear cells. Clin. Transl. Sci. 5 (2012), 32–38.
42. [42] Drummond, M.J., McCarthy, J.J., Fry, C.S., Esser, K.A., Rasmussen, B.B., Aging differentially affects human skeletal muscle microRNA expression at rest and after an anabolic stimulus of resistance exercise and essential amino acids. Am. J. Physiol. Endocrinol. Metab. 295 (2008), E1333–E1340.
43. [43] Xu, J., Lombardi, G., Jiao, W., Banfi, G., Effects of exercise on bone status in female subjects, from young girls to postmenopausal women: an overview of systematic reviews and meta-analyses. Sports Med., 2016, 10.1007/s40279-016-0494-0 (Epub Ahead of Print.).
44. [44] Qi, Z., Liu, W., Lu, J., The mechanisms underlying the beneficial effects of exercise on bone remodeling: roles of bone-derived cytokines and microRNAs. Prog. Biophys. Mol. Biol., 2016, 10.1016/j.pbiomolbio.2016.05.010 (Epub Ahead of Print).
45. [45] Gamez, B., Rodriguez-Carballo, E., Ventura, F., MicroRNAs and post-transcriptional regulation of skeletal development. J. Mol. Endocrinol. 52 (2014), R179–R197.
46. [46] Lombardi, G., Sansoni, V., Perego, S., Vernillo, G., Bonzanni, M., Merati, G., et al. Bone-specific circulating miRNA profile changes over an 8-week repeated sprint training protocol. Endocr. Abstr., 41, 2016, GP31.
47. [47] Chen, J., Qiu, M., Dou, C., Cao, Z., Dong, S., MicroRNAs in bone balance and osteoporosis. Drug Dev. Res. 76 (2015), 235–245.
48. [48] Seeliger, C., Karpinski, K., Haug, A.T., Vester, H., Schmitt, A., Bauer, J.S., et al. Five freely circulating miRNAs and bone tissue miRNAs are associated with osteoporotic fractures. J. Bone Miner. Res. 29 (2014), 1718–1728.
49. [49] Rullman, E., Mekjavic, I.B., Fischer, H., Eiken, O., PlanHab (planetary habitat simulation): the combined and separate effects of 21 days bed rest and hypoxic confinement on human skeletal muscle miRNA expression. Physiol. Rep., 4(8), 2016.
50. [50] Bork-Jensen, J., Scheele, C., Christophersen, D.V., Nilsson, E., Friedrichsen, M., Fernandez-Twinn, D.S., et al. Glucose tolerance is associated with differential expression of microRNAs in skeletal muscle: results from studies of twins with and without type 2 diabetes. Diabetologia 58 (2015), 363–373.
51. [51] Alibegovic, A.C., Sonne, M.P., Hojbjerre, L., Bork-Jensen, J., Jacobsen, S., Nilsson, E., et al. Insulin resistance induced by physical inactivity is associated with multiple transcriptional changes in skeletal muscle in young men. Am. J. Physiol. Endocrinol. Metab. 299 (2010), E752–E763.
52. [52] Gallagher, I.J., Scheele, C., Keller, P., Nielsen, A.R., Remenyi, J., Fischer, C.P., et al. Integration of microRNA changes in vivo identifies novel molecular features of muscle insulin resistance in type 2 diabetes. Genome Med., 2, 2010, 9.
53. [53] Wahlquist, C., Jeong, D., Rojas-Munoz, A., Kho, C., Lee, A., Mitsuyama, S., et al. Inhibition of miR-25 improves cardiac contractility in the failing heart. Nature 508 (2014), 531–535.
54. [54] Becker, N., Lockwood, C.M., Pre-analytical variables in miRNA analysis. Clin. Biochem. 46 (2013), 861–868.
55. [55] Bonini, P., Plebani, M., Ceriotti, F., Rubboli, F., Errors in laboratory medicine. Clin. Chem. 48 (2002), 691–698.
56. [56] Lippi, G., Guidi, G.C., Mattiuzzi, C., Plebani, M., Preanalytical variability: the dark side of the moon in laboratory testing. Clin. Chem. Lab. Med. 44 (2006), 358–365.
57. [57] Kavsak, P.A., What is in that sample? A pertinent question when assessing quality for patient laboratory results and beyond. Clin. Biochem. 48 (2015), 465–466.
58. [58] van Dongen-Lases, E.C., Cornes, M.P., Grankvist, K., Ibarz, M., Kristensen, G.B., Lippi, G., et al. Patient identification and tube labelling — a call for harmonisation. Clin. Chem. Lab. Med. 54 (2016), 1141–1145.
59. [59] Lippi, G., Chance, J.J., Church, S., Dazzi, P., Fontana, R., Giavarina, D., et al. Preanalytical quality improvement: from dream to reality. Clin. Chem. Lab. Med. 49 (2011), 1113–1126.
60. [60] Supak-Smolcic, V., Antoncic, D., Ozanic, D., Vladilo, I., Bilic-Zulle, L., Influence of a prolonged fasting and mild activity on routine laboratory tests. Clin. Biochem. 48 (2015), 85–88.
61. [61] Banfi, G., Dolci, A., Preanalytical phase of sport biochemistry and haematology. J. Sports Med. Phys. Fitness 43 (2003), 223–230.
62. [62] Lima-Oliveira, G., Guidi, G.C., Salvagno, G.L., Brocco, G., Danese, E., Lippi, G., Estimation of the imprecision on clinical chemistry testing due to fist clenching and maintenance during venipuncture. Clin. Biochem. 49 (2016), 1364–1367.
63. [63] Lima-Oliveira, G., Lippi, G., Salvagno, G.L., Montagnana, M., Picheth, G., Guidi, G.C., The effective reduction of tourniquet application time after minor modification of the CLSI H03-A6 blood collection procedure. Biochem. Med. 23 (2013), 308–315.
64. [64] WADA, The world anti-doping code: athlete biological passport operating guidelines and compilation of required elements. Version 3 2012:1-52. http://www.wada-ama.org/Documents/Science_Medicine/Athlete_Biological_Passport/WADA_ABP_OperatingGuidelines_version_3.0.pdf, 2012.
65. [65] Lombardi, G., Perego, S., Luzi, L., Banfi, G., A four-season molecule: osteocalcin. Updates in its physiological roles. Endocrine 48 (2015), 394–404.
66. [66] Lanteri, P., Lombardi, G., Colombini, A., Banfi, G., Vitamin D in exercise: physiologic and analytical concerns. Clin. Chim. Acta 415 (2013), 45–53.
67. [67] Lombardi, G., Banfi, G., Effects of sample matrix and storage conditions on full-length visfatin measurement in blood. Clin. Chim. Acta 440 (2015), 140–142.
68. [68] Lanteri, P., Lombardi, G., Colombini, A., Grasso, D., Banfi, G., Stability of osteopontin in plasma and serum. Clin. Chem. Lab. Med. 50 (2012), 1979–1984.
69. [69] Jarry, J., Schadendorf, D., Greenwood, C., Spatz, A., van Kempen, L.C., The validity of circulating microRNAs in oncology: five years of challenges and contradictions. Mol. Oncol. 8 (2014), 819–829.
70. [70] Chen, X., Liang, H., Zhang, J., Zen, K., Zhang, C.Y., Secreted microRNAs: a new form of intercellular communication. Trends Cell Biol. 22 (2012), 125–132.
71. [71] Arroyo, J.D., Chevillet, J.R., Kroh, E.M., Ruf, I.K., Pritchard, C.C., Gibson, D.F., et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 5003–5008.
72. [72] Li, L., Zhu, D., Huang, L., Zhang, J., Bian, Z., Chen, X., et al. Argonaute 2 complexes selectively protect the circulating microRNAs in cell-secreted microvesicles. PLoS One, 7, 2012, e46957.
73. [73] El-Hefnawy, T., Raja, S., Kelly, L., Bigbee, W.L., Kirkwood, J.M., Luketich, J.D., et al. Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics. Clin. Chem. 50 (2004), 564–573.
74. [74] Mitchell, P.S., Parkin, R.K., Kroh, E.M., Fritz, B.R., Wyman, S.K., Pogosova-Agadjanyan, E.L., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 10513–10518.
75. [75] Kroh, E.M., Parkin, R.K., Mitchell, P.S., Tewari, M., Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 50 (2010), 298–301.
76. [76] Cheng, H.H., Yi, H.S., Kim, Y., Kroh, E.M., Chien, J.W., Eaton, K.D., et al. Plasma processing conditions substantially influence circulating microRNA biomarker levels. PLoS One, 8, 2013, e64795.
77. [77] Kirschner, M.B., Kao, S.C., Edelman, J.J., Armstrong, N.J., Vallely, M.P., van Zandwijk, N., et al. Haemolysis during sample preparation alters microRNA content of plasma. PLoS One, 6, 2011, e24145.
78. [78] Willeit, P., Zampetaki, A., Dudek, K., Kaudewitz, D., King, A., Kirkby, N.S., et al. Circulating microRNAs as novel biomarkers for platelet activation. Circ. Res. 112 (2013), 595–600.
79. [79] Blondal, T., Jensby Nielsen, S., Baker, A., Andreasen, D., Mouritzen, P., Wrang Teilum, M., et al. Assessing sample and miRNA profile quality in serum and plasma or other biofluids. Methods 59 (2013), S1–S6.
80. [80] Livesey, J.H., Ellis, M.J., Evans, M.J., Pre-analytical requirements. Clin. Biochem. Rev. 29:Suppl 1 (2008), S11–S15.
81. [81] Kavsak, P.A., Hammett-Stabler, C.A., Clinical biochemistry year in review — the clinical “good”, the analytical “bad”, and the “ugly” laboratory practices. Clin. Biochem. 47 (2014), 255–256.
82. [82] Boeckel, J.N., Thome, C.E., Leistner, D., Zeiher, A.M., Fichtlscherer, S., Dimmeler, S., Heparin selectively affects the quantification of microRNAs in human blood samples. Clin. Chem. 59 (2013), 1125–1127.
83. [83] Garcia, M.E., Blanco, J.L., Caballero, J., Gargallo-Viola, D., Anticoagulants interfere with PCR used to diagnose invasive aspergillosis. J. Clin. Microbiol. 40 (2002), 1567–1568.
84. [84] Zampetaki, A., Mayr, M., Analytical challenges and technical limitations in assessing circulating miRNAs. Thromb. Haemost. 108 (2012), 592–598.
85. [85] Kim, D.J., Linnstaedt, S., Palma, J., Park, J.C., Ntrivalas, E., Kwak-Kim, J.Y., et al. Plasma components affect accuracy of circulating cancer-related microRNA quantitation. J. Mol. Diagn. 14 (2012), 71–80.
86. [86] Turchinovich, A., Weiz, L., Langheinz, A., Burwinkel, B., Characterization of extracellular circulating microRNA. Nucleic Acids Res. 39 (2011), 7223–7233.
87. [87] WADA, World anti-doping agency. Requirements for passport operation from international standard for testing and international standard for laboratories. Available at http://www.wada-ama.org/Documents/Resources/Guidelines/WADA_ABP_OperatingGuidelines_EN_2.1.pdf, 2011 (Accessed: October 2011. < http://www.wada-ama.org/Documents/Resources/Guidelines/WADA_ABP_OperatingGuidelines_EN_2.1.pdf>).
88. [88] Saugy, M., Lundby, C., Robinson, N., Monitoring of biological markers indicative of doping: the athlete biological passport. Br. J. Sports Med. 48 (2014), 827–832.
89. [89] Lombardi, G., Lanteri, P., Colombini, A., Banfi, G., Blood biochemical markers of bone turnover: pre-analytical and technical aspects of sample collection and handling. Clin. Chem. Lab. Med. 50 (2012), 771–789.
90. [90] Mestdagh, P., Van Vlierberghe, P., De Weer, A., Muth, D., Westermann, F., Speleman, F., et al. A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol., 10, 2009, R64.
91. [91] Segura, J., Lundby, C., Blood doping: potential of blood and urine sampling to detect autologous transfusion. Br. J. Sports Med. 48 (2014), 837–841.
92. [92] Lombardi, G., Colombini, A., Lanteri, P., Banfi, G., Reticulocytes in sports medicine: an update. Adv. Clin. Chem. 59 (2013), 125–153.
93. [93] Banfi, G., Lombardi, G., Colombini, A., Lippi, G., Analytical variability in sport hematology: its importance in an antidoping setting. Clin. Chem. Lab. Med. 49 (2011), 779–782.
94. [94] Brisswalter, J., Louis, J., Vitamin supplementation benefits in master athletes. Sports Med. 44 (2014), 311–318.
95. [95] Di Luigi, L., Supplements and the endocrine system in athletes. Clin. Sports Med. 27 (2008), 131–151 ix.
96. [96] Garzon, R., Pichiorri, F., Palumbo, T., Visentini, M., Aqeilan, R., Cimmino, A., et al. MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene 26 (2007), 4148–4157.
97. [97] Fisher, J.N., Terao, M., Fratelli, M., Kurosaki, M., Paroni, G., Zanetti, A., et al. MicroRNA networks regulated by all-trans retinoic acid and lapatinib control the growth, survival and motility of breast cancer cells. Oncotarget 6 (2015), 13176–13200.
98. [98] Khan, S., Wall, D., Curran, C., Newell, J., Kerin, M.J., Dwyer, R.M., MicroRNA-10a is reduced in breast cancer and regulated in part through retinoic acid. BMC Cancer, 15, 2015, 345.
99. [99] Warth, S.C., Hoefig, K.P., Hiekel, A., Schallenberg, S., Jovanovic, K., Klein, L., et al. Induced miR-99a expression represses Mtor cooperatively with miR-150 to promote regulatory T-cell differentiation. EMBO J. 34 (2015), 1195–1213.
100. [100] Wang, Z., Fan, X., Zhang, R., Lin, Z., Lu, T., Bai, X., et al. Integrative analysis of mRNA and miRNA array data reveals the suppression of retinoic acid pathway in regulatory T cells of Graves’ disease. J. Clin. Endocrinol. Metab. 99 (2014), E2620–E2627.
101. [101] Zhu, X., Gao, G., Chu, K., Yang, X., Ren, S., Li, Y., et al. Inhibition of RAC1-GEF DOCK3 by miR-512-3p contributes to suppression of metastasis in non-small cell lung cancer. Int. J. Biochem. Cell Biol. 61 (2015), 103–114.
102. [102] Wang, X.S., Gong, J.N., Yu, J., Wang, F., Zhang, X.H., Yin, X.L., et al. MicroRNA-29a and microRNA-142-3p are regulators of myeloid differentiation and acute myeloid leukemia. Blood 119 (2012), 4992–5004.
103. [103] Khee, S.G., Yusof, Y.A., Makpol, S., Expression of senescence-associated microRNAs and target genes in cellular aging and modulation by tocotrienol-rich fraction. Oxidative Med. Cell. Longev., 2014, 2014, 725929.
104. [104] Fiorino, S., Bacchi-Reggiani, L., Sabbatani, S., Grizzi, F., di Tommaso, L., Masetti, M., et al. Possible role of tocopherols in the modulation of host microRNA with potential antiviral activity in patients with hepatitis B virus-related persistent infection: a systematic review. Br. J. Nutr. 112 (2014), 1751–1768.
105. [105] Gontero, P., Marra, G., Soria, F., Oderda, M., Zitella, A., Baratta, F., et al. A randomized double-blind placebo controlled phase I–II study on clinical and molecular effects of dietary supplements in men with precancerous prostatic lesions. Chemoprevention or “chemopromotion”?. Prostate 75 (2015), 1177–1186.
106. [106] Ji, X., Wang, Z., Geamanu, A., Goja, A., Sarkar, F.H., Gupta, S.V., Delta-tocotrienol suppresses Notch-1 pathway by upregulating miR-34a in nonsmall cell lung cancer cells. Int. J. Cancer 131 (2012), 2668–2677.
107. + cells from radiation injury. PLoS One, 10, 2015, e0122258.
108. [108] Gaedicke, S., Zhang, X., Schmelzer, C., Lou, Y., Doering, F., Frank, J., et al. Vitamin E dependent microRNA regulation in rat liver. FEBS Lett. 582 (2008), 3542–3546.
109. [109] Beckett, E.L., Martin, C., Choi, J.H., King, K., Niblett, S., Boyd, L., et al. Folate status, folate-related genes and serum miR-21 expression: implications for miR-21 as a biomarker. BBA Clin. 4 (2015), 45–51.
110. [110] Perez-Carbonell, L., Sinicrope, F.A., Alberts, S.R., Oberg, A.L., Balaguer, F., Castells, A., et al. MiR-320e is a novel prognostic biomarker in colorectal cancer. Br. J. Cancer 113 (2015), 83–90.
111. [111] Tian, Y., Xue, Y., Ruan, G., Cheng, K., Tian, J., Qiu, Q., et al. Interaction of serum microRNAs and serum folate with the susceptibility to pancreatic cancer. Pancreas 44 (2015), 23–30.
112. [112] He, C.S., Aw Yong, X.H., Walsh, N.P., Gleeson, M., Is there an optimal vitamin D status for immunity in athletes and military personnel?. Exerc. Immunol. Rev. 22 (2016), 42–64.
113. [113] Giangreco, A.A., Nonn, L., The sum of many small changes: microRNAs are specifically and potentially globally altered by vitamin D3 metabolites. J. Steroid Biochem. Mol. Biol. 136 (2013), 86–93.
114. [114] Campbell, M.J., Vitamin D and the RNA transcriptome: more than mRNA regulation. Front. Physiol., 5, 2014, 181.
115. [115] Lisse, T.S., Adams, J.S., Hewison, M., Vitamin D and microRNAs in bone. Crit. Rev. Eukaryot. Gene Expr. 23 (2013), 195–214.
116. [116] Ma, Y., Trump, D.L., Johnson, C.S., Vitamin D and miRNAs in cancer. Curr. Gene. Ther. 14 (2014), 269–275.
117. [117] Beckett, E.L., Martin, C., Duesing, K., Jones, P., Furst, J., Yates, Z., et al. Vitamin D receptor genotype modulates the correlation between vitamin D and circulating levels of let-7a/b and vitamin D intake in an elderly cohort. J. Nutrigenet. Nutrigenomics 7 (2014), 264–273.
118. [118] Lombardi, G., Lippi, G., Banfi, G., Iron requirements and iron status of athletes. Moughan, R.J., (eds.) Sports Nutrition, 2013, Wiley-Blackwell, John Wiley & Sons, Inc., Hoboken, NJ, USA, 229–241.
119. [119] Silva, B., Faustino, P., An overview of molecular basis of iron metabolism regulation and the associated pathologies. Biochim. Biophys. Acta 2015 (1852), 1347–1359.
120. [120] Weitz, S.H., Gong, M., Barr, I., Weiss, S., Guo, F., Processing of microRNA primary transcripts requires heme in mammalian cells. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 1861–1866.
121. [121] Li, Y., Lin, L., Li, Z., Ye, X., Xiong, K., Aryal, B., et al. Iron homeostasis regulates the activity of the microRNA pathway through poly(C)-binding protein 2. Cell Metab. 15 (2012), 895–904.
122. [122] Chen, J., Xu, X., Diet, epigenetic, and cancer prevention. Adv. Genet. 71 (2010), 237–255.
123. [123] Sakai, A., Suzuki, H., microRNA and pain. Adv. Exp. Med. Biol. 888 (2015), 17–39.
124. [124] Lotsch, J., Doehring, A., Mogil, J.S., Arndt, T., Geisslinger, G., Ultsch, A., Functional genomics of pain in analgesic drug development and therapy. Pharmacol. Ther. 139 (2013), 60–70.
125. [125] Vliegenthart, A.D., Shaffer, J.M., Clarke, J.I., Peeters, L.E., Caporali, A., Bateman, D.N., et al. Comprehensive microRNA profiling in acetaminophen toxicity identifies novel circulating biomarkers for human liver and kidney injury. Sci. Rep., 5, 2015, 15501.
126. [126] Yang, X., Salminen, W.F., Shi, Q., Greenhaw, J., Gill, P.S., Bhattacharyya, S., et al. Potential of extracellular microRNAs as biomarkers of acetaminophen toxicity in children. Toxicol. Appl. Pharmacol. 284 (2015), 180–187.
127. [127] Lundby, C., Millet, G.P., Calbet, J.A., Bartsch, P., Subudhi, A.W., Does ‘altitude training’ increase exercise performance in elite athletes?. Br. J. Sports Med. 46 (2012), 792–795.
128. [128] Guimbellot, J.S., Erickson, S.W., Mehta, T., Wen, H., Page, G.P., Sorscher, E.J., et al. Correlation of microRNA levels during hypoxia with predicted target mRNAs through genome-wide microarray analysis. BMC Med. Genet., 2, 2009, 15.
129. [129] Chen, F., Zhang, W., Liang, Y., Huang, J., Li, K., Green, C.D., et al. Transcriptome and network changes in climbers at extreme altitudes. PLoS One, 7, 2012, e31645.
130. [130] Yan, Y., Shi, Y., Wang, C., Guo, P., Wang, J., Zhang, C.Y., et al. Influence of a high-altitude hypoxic environment on human plasma microRNA profiles. Sci. Rep., 5, 2015, 15156.
131. [131] Lombardi, G., Lanteri, P., Colombini, A., Lippi, G., Banfi, G., Stability of haematological parameters and its relevance on the athlete's biological passport model. Sports Med. 41 (2011), 1033–1042.
132. [132] Robinson, N., Giraud, S., Schumacher, Y.O., Saugy, M., Influence of transport and time on blood variables commonly measured for the athlete biological passport. Drug Test. Anal. 8 (2016), 199–207.
133. [133] Ashenden, M., Sharpe, K., Plowman, J., Allbon, G., Lobigs, L., Baron, A., et al. Stability of athlete blood passport parameters during air freight. Int. J. Lab. Hematol. 36 (2014), 505–513.
134. [134] Schumacher, Y.O., Klodt, F., Nonis, D., Pottgiesser, T., Alsayrafi, M., Bourdon, P.C., et al. The impact of long-haul air travel on variables of the athlete's biological passport. Int. J. Lab. Hematol. 34 (2012), 641–647.
135. [135] Lippi, G., Lima-Oliveira, G., Salvagno, G.L., Montagnana, M., Gelati, M., Picheth, G., et al. Influence of a light meal on routine haematological tests. Blood Transfus. 8 (2010), 94–99.
136. [136] Leuenberger, N., Baume, N., Robinson, N., Saugy, M., Pre-analytical and analytical aspects of EDTA-plasma iron measurement. Drug Test. Anal., 2015.
137. [137] Leuenberger, N., Saugy, M., Circulating microRNAs: the future of biomarkers in anti-doping field. Adv. Exp. Med. Biol. 888 (2015), 401–408.
138. [138] Kelly, B.N., Haverstick, D.M., Lee, J.K., Thorner, M.O., Vance, M.L., Xin, W., et al. Circulating microRNA as a biomarker of human growth hormone administration to patients. Drug Test. Anal. 6 (2014), 234–238.
139. [139] Salamin, O., Jaggi, L., Baume, N., Robinson, N., Saugy, M., Leuenberger, N., Circulating microRNA-122 as potential biomarker for detection of testosterone abuse. PLoS One, 11, 2016, e0155248.
140. [140] Leuenberger, N., Schumacher, Y.O., Pradervand, S., Sander, T., Saugy, M., Pottgiesser, T., Circulating microRNAs as biomarkers for detection of autologous blood transfusion. PLoS One, 8, 2013, e66309.
141. [141] Leuenberger, N., Jan, N., Pradervand, S., Robinson, N., Saugy, M., Circulating microRNAs as long-term biomarkers for the detection of erythropoiesis-stimulating agent abuse. Drug Test. Anal. 3 (2011), 771–776.